Le20: Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label

Outcome Measure:

To characterize the molecular and cell biology of the tumor cells in lymphoma.

Outcome Time Frame:

6 months

Safety Issue:

No

Principal Investigator

Wen-Kai Weng

Investigator Role:

Principal Investigator

Investigator Affiliation:

Stanford University

Authority:

United States: Institutional Review Board

Study ID:

LYMNHL0031

NCT ID:

NCT00398372

Start Date:

November 2000

Completion Date:

September 2009

Related Keywords:

• Lymphoma, Non-Hodgkin
• Lymphomas: Non-Hodgkin
• Lymphomas: Non-Hodgkin Cutaneous Lymphoma
• Lymphomas: Non-Hodgkin Diffuse Large B-Cell
• Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell
• Lymphomas: Non-Hodgkin Mantle Cell
• Lymphomas: Non-Hodgkin Marginal Zone
• Lymphomas: Non-Hodgkin Peripheral T-Cell
• Lymphomas: Non-Hodgkin Waldenstr Macroglobulinemia
• Lymphoma
• Lymphoma, Non-Hodgkin
• Waldenstrom Macroglobulinemia